Latest Breaking News On - Site directed enzyme enhancement therapy - Page 8 : comparemela.com
Investegate |Gain Therapeutics Announcements | Gain Therapeutics: Gain Therapeutics, Inc Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson s Disease
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Gain Therapeutics, Inc Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model
Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase
Compounds decrease both phosphorylated and aggregated α
-synuclein levels in vitro and in vivo
BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pre-clinical data from its GBA1 Parkinson’s disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, a research conference dedicated to Parkinson’s disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4, 2021.
Gain Therapeutics
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.
(2)
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. ( Gain ) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board. We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain, said Eric Richman, Chief Executive Officer at Gain. Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Therapy (Se
vimarsana © 2020. All Rights Reserved.